- Home
- GNLX vs ASRT Comparison
GNLX vs ASRT Comparison
Compare GNLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | ASRT |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 76.0M |
| IPO Year | 2022 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GNLX | ASRT |
|---|---|---|
| Price | $2.57 | $18.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $19.80 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 150.5K | 135.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $0.51 |
| 52 Week High | $8.54 | $20.45 |
Technical Indicators
Market Signals| Indicator | GNLX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 74.09 |
| Support Level | $2.54 | $0.69 |
| Resistance Level | $3.00 | $20.45 |
| Average True Range (ATR) | 0.16 | 1.42 |
| MACD | 0.01 | 0.50 |
| Stochastic Oscillator | 56.00 | 86.48 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.